Scholar Rock (NASDAQ:SRRK) Insider Mo Qatanani Sells 8,484 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Mo Qatanani sold 8,484 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $47.07, for a total transaction of $399,341.88. Following the completion of the sale, the insider directly owned 98,445 shares in the company, valued at approximately $4,633,806.15. This represents a 7.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mo Qatanani also recently made the following trade(s):

• On Tuesday, February 17th, Mo Qatanani sold 7,989 shares of Scholar Rock stock. The shares were sold at an average price of $46.53, for a total value of $371,728.17.
• On Thursday, January 22nd, Mo Qatanani sold 14,898 shares of Scholar Rock stock. The shares were sold at an average price of $46.71, for a total value of $695,885.58.
• On Friday, January 16th, Mo Qatanani sold 8,406 shares of Scholar Rock stock. The shares were sold at an average price of $44.48, for a total transaction of $373,898.88.
• On Wednesday, January 14th, Mo Qatanani sold 13,112 shares of Scholar Rock stock. The stock was sold at an average price of $45.20, for a total transaction of $592,662.40.
• On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The stock was sold at an average price of $45.21, for a total value of $6,169,447.02.

Scholar Rock Stock Performance

NASDAQ:SRRK traded down $1.59 on Thursday, hitting $45.39. The company’s stock had a trading volume of 150,807 shares, compared to its average volume of 951,627. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a one year low of $22.71 and a one year high of $49.82. The stock has a fifty day moving average of $45.31 and a two-hundred day moving average of $38.68. The firm has a market capitalization of $4.63 billion, a P/E ratio of -14.40 and a beta of 0.67.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on SRRK shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday, January 22nd. HC Wainwright increased their target price on Scholar Rock from $44.00 to $58.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Barclays boosted their price target on Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $50.00 target price on shares of Scholar Rock in a report on Friday, November 14th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $51.14.

Hedge Funds Weigh In On Scholar Rock

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SRRK. Invesco Ltd. increased its position in shares of Scholar Rock by 21.0% in the fourth quarter. Invesco Ltd. now owns 82,462 shares of the company’s stock worth $3,632,000 after purchasing an additional 14,291 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in Scholar Rock during the fourth quarter worth about $308,000. Mackenzie Financial Corp bought a new position in Scholar Rock in the 4th quarter valued at about $221,000. Empowered Funds LLC acquired a new position in shares of Scholar Rock in the 4th quarter valued at approximately $114,000. Finally, KVP Capital Advisors LP bought a new stake in shares of Scholar Rock during the 4th quarter worth approximately $1,982,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).